Pyxis Oncology (NASDAQ:PYXS – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.
Valuation and Earnings
This table compares Pyxis Oncology and Pluri”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pyxis Oncology | $11.04 million | 17.12 | -$79.62 million | ($1.30) | -1.22 |
| Pluri | $1.02 million | 13.03 | -$23.82 million | ($2.65) | -0.40 |
Pluri has lower revenue, but higher earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Pyxis Oncology and Pluri, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pyxis Oncology | 1 | 0 | 7 | 0 | 2.75 |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
Pyxis Oncology presently has a consensus target price of $8.71, indicating a potential upside of 451.54%. Given Pyxis Oncology’s stronger consensus rating and higher possible upside, analysts clearly believe Pyxis Oncology is more favorable than Pluri.
Risk and Volatility
Pyxis Oncology has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.
Insider and Institutional Ownership
39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 10.5% of Pyxis Oncology shares are held by insiders. Comparatively, 43.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Pyxis Oncology and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pyxis Oncology | N/A | -252.36% | -120.63% |
| Pluri | -1,943.87% | N/A | -106.56% |
Summary
Pyxis Oncology beats Pluri on 9 of the 14 factors compared between the two stocks.
About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biotechnology company developing antibody-based medicines for people with difficult-to-treat cancers. Its research focuses on targeted therapies intended to attack tumors while limiting effects on healthy tissue. The company’s pipeline includes PYX-201, an investigational antibody-drug conjugate designed to target EDB+ fibronectin, a protein found in the tumor microenvironment. The program reflects Pyxis Oncology’s broader approach of using antibodies to direct cancer-fighting agents to tumor-associated targets.
About Pluri
Pluri Ltd. is an Israel-based biotechnology company developing cell-based products and technologies. Its therapeutic research centers on PLX cells, derived from human placental tissue and expanded using the company’s cell-manufacturing platform. Pluri has investigated these cells for potential use in a range of medical conditions; its therapies remain in development. The company also applies its cell-expansion technology to areas beyond medicine, including food technology and agriculture, where it is exploring cell-based products and production methods.
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
